Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 4, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) under the Company's ShareSave Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Volume |
|---|---|---|---|
| December 3, 2018 | Ordinary Shares (25 pence each) | £10.13 | 888 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records two identical transactions executed on the same date by different executives.
Management Commentary and Risks
There is no management commentary, guidance, outlook, or discussion of risks and contingencies in this filing. The content is limited to regulatory disclosure of share option exercises.
- Transaction 1: Mr. R G Connor (President, Global Vaccines) acquired 888 Ordinary Shares at £10.13 per share following the exercise of options granted on October 29, 2015.
- Transaction 2: Mr. D Redfern (Chief Strategy Officer) acquired 888 Ordinary Shares at £10.13 per share following the exercise of options granted on October 29, 2015.
- Venue: London Stock Exchange (XLON).
Investor Verification Points
- Verify the total number of shares held by Mr. R G Connor and Mr. D Redfern post-transaction to assess their overall equity exposure.
- Confirm the current market price of GSK Ordinary Shares relative to the £10.13 exercise price to evaluate the immediate economic benefit realized by the executives.
- Review the full terms of the ShareSave Plan options granted on October 29, 2015, to understand vesting schedules and future potential exercises.